Making The Case For A Legislative Deal On Drug Pricing
Executive Summary
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.
You may also be interested in...
Wall Street To Pharma: Strike A Deal On Drug Pricing And Resolve Uncertainty About Reform
Pricing policies aimed at lowering Medicare Part B costs should be ‘relatively easy’ to accomplish but they wouldn’t be as effective in satisfying industry critics as reforms in Part D, securities analyst Geoffrey Porges says.
Insulin Report Revives Senate Finance Committee Push On Drug Pricing Legislation
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
Insulin Report Revives Senate Finance Committee Push On Drug Pricing Legislation
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.